Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Surface Oncology, Inc. (SURF)

1.07   -0.01 (-0.93%) 09-07 16:00
Open: 1.06 Pre. Close: 1.08
High: 1.09 Low: 1.01
Volume: 1,462,284 Market Cap: 65(M)

Technical analysis

as of: 2023-09-27 4:22:22 PM
Short-term rate:       
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Mid-term rate:       
Target: Six months: 1.3     One year: 1.52
Support: Support1: 0.93    Support2: 0.82
Resistance: Resistance1: 1.12    Resistance2: 1.3
Pivot: 1.03
Moving Average: MA(5): 1.07     MA(20): 1
MA(100): 0.84     MA(250): 0.87
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 79.7     %D(3): 81.7
RSI: RSI(14): 61.4
52-week: High: 1.42  Low: 0.55
Average Vol(K): 3-Month: 811 (K)  10-Days: 414 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ SURF ] has closed below upper band by 31.0%. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.07 - 1.08 1.08 - 1.08
Low: 1.06 - 1.06 1.06 - 1.07
Close: 1.06 - 1.07 1.07 - 1.08

Company Description

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Wed, 20 Sep 2023
Efficacy of copper nanoparticles encapsulated in soya lecithin ... -

Thu, 31 Aug 2023
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences - Yahoo Finance

Tue, 29 Aug 2023
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ... - GlobeNewswire

Tue, 15 Aug 2023
Surface Oncology And Coherus BioSciences: Does A Buyout Equal ... - Seeking Alpha

Wed, 02 Aug 2023
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023 - Yahoo Finance

Tue, 01 Aug 2023
Moore Kuehn Encourages PACW, NEWR, CFMS, and SURF ... - GlobeNewswire

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 61 (M)
Shares Float 49 (M)
% Held by Insiders 7.2 (%)
% Held by Institutions 46 (%)
Shares Short 165 (K)
Shares Short P.Month 285 (K)

Stock Financials

EPS -1.56
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.81
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -41.5
Return on Equity (ttm) -105.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.61
Sales Per Share 0
EBITDA (p.s.) -1.37
Qtrly Earnings Growth 0
Operating Cash Flow -84 (M)
Levered Free Cash Flow -52 (M)

Stock Valuations

PE Ratio -0.69
PEG Ratio 0
Price to Book value 1.32
Price to Sales 0
Price to Cash Flow -0.78

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.